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Abstract
Background
The importance of Cryptosporidium as a pediatric enteropathogen in developing countries
is recognized.
Methods
Data from the Global Enteric Multicenter Study (GEMS), a 3-year, 7-site, case-control study
of moderate-to-severe diarrhea (MSD) and GEMS-1A (1-year study of MSD and less-severe
diarrhea [LSD]) were analyzed. Stools from 12,110 MSD and 3,174 LSD cases among chil-
dren aged <60months and from 21,527 randomly-selected controls matched by age, sex and
community were immunoassay-tested forCryptosporidium. Species of a subset ofCrypto-
sporidium-positive specimens were identified by PCR; GP60 sequencing identified anthropo-
noticC. parvum. Combined annualCryptosporidium-attributable diarrhea incidences among
children aged <24months for African and Asian GEMS sites were extrapolated to sub-Saha-
ran Africa and South Asian regions to estimate region-wide MSD and LSD burdens. Attribut-
able and excess mortality due toCryptosporidium diarrhea were estimated.
Findings
Cryptosporidium was significantly associated with MSD and LSD below age 24months.
AmongCryptosporidium-positive MSD cases,C. hominiswas detected in 77.8% (95%CI,
73.0%-81.9%) andC. parvum in 9.9% (95%CI, 7.1%-13.6%); 92% ofC. parvum tested were
anthroponotic genotypes. AnnualCryptosporidium-attributable MSD incidence was 3.48 (95%
CI, 2.27–4.67) and 3.18 (95%CI, 1.85–4.52) per 100 child-years in African and Asian infants,
respectively, and 1.41 (95%CI, 0.73–2.08) and 1.36 (95%CI, 0.66–2.05) per 100 child-years in
toddlers. CorrespondingCryptosporidium-attributable LSD incidences per 100 child-years were
2.52 (95%CI, 0.33–5.01) and 4.88 (95%CI, 0.82–8.92) in infants and 4.04 (95%CI, 0.56–7.51)
and 4.71 (95%CI, 0.24–9.18) in toddlers. We estimate 2.9 and 4.7 millionCryptosporidium-
attributable cases annually in children aged <24months in the sub-Saharan Africa and India/
Pakistan/Bangladesh/Nepal/Afghanistan regions, respectively, and ~202,000Cryptosporidium-
attributable deaths (regions combined). ~59,000 excess deaths occurred amongCryptosporid-
ium-attributable diarrhea cases over expected if cases had beenCryptosporidium-negative.
Conclusions
The enormous African/Asian Cryptosporidium disease burden warrants investments to
develop vaccines, diagnostics and therapies.
Author Summary
Cryptosporidium is a protozoan that causes diarrhea and malnutrition in young children
in developing countries, and is associated with diarrhea cases and outbreaks in developed
CryptosporidiumDiarrheal Disease Burden
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countries. To date, limited information exists on the burden of Cryptosporidium diarrheal
disease in sub-Saharan Africa and South Asia, where most diarrheal disease deaths occur.
We estimated the burden of Cryptosporidium-diarrhea and associated deaths in these
regions using data from the Global Enteric Multicenter Study (GEMS). Cryptosporidium
was associated with diarrhea mainly in children aged<24 months. Infections began in the
first few months of life but clinical episodes of Cryptosporidium-associated diarrhea illness
peaked at age 6–11 months. The annual number of Cryptosporidium-attributable diarrhea
episodes was estimated at 2.9 and 4.7 million in children aged<24 months in sub-Saharan
Africa and in the India/Pakistan/Bangladesh/Afghanistan/Nepal region of South Asia,
respectively. In both regions combined, Cryptosporidium is estimated to contribute to
approximately 202,000 deaths per year, and to ~59,000 more deaths in Cryptosporidium-
attributable cases than if those cases had been negative for Cryptosporidium. Our study
highlights the enormous burden attributable to Cryptosporidium in Africa and Asia, which
underscores the need for developing vaccines and treatments to reduce this burden.
Introduction
Cryptosporidium, the highly infectious protozoan that causes diarrhea in immunocompetent
and immunocompromised subjects [1–4], is transmitted via contaminated water or food
[1,3,5], swimming or bathing in surface waters [1,3] and by direct person-to-person contact
[6], particularly in developing country settings of suboptimal sanitation and limited access to
safe drinking water [1,3,4]. Clinical cryptosporidiosis ranges from self-limited mild diarrhea
(most commonly) to more severe forms such as persistent diarrhea (lasting 14 days or more)
leading to malnutrition, hospitalizations and even death [1,2,5,7–13]. Immunocompromised
hosts, e.g., persons with HIV/AIDS and malnourished children in developing countries, are
more prone to develop severe clinical illness [1,14]. Fecal shedding of Cryptosporidium oocysts
can persist for weeks after clinical illness resolves [15,16]. Since Cryptosporidium oocysts toler-
ate chlorination, waterborne outbreaks also occur in industrialized countries [1,3,5].
Recently, the Global Enteric Multicenter Study (GEMS) elucidated the relative impor-
tance of Cryptosporidium versus many other enteropathogens as a cause of medically-
attended diarrhea in young children in developing countries of sub-Saharan Africa (SSA)
and South Asia [10], where most young child diarrheal deaths occur. Cryptosporidium was
the second leading cause (5–15%) of moderate-to-severe diarrhea (MSD) in infants at all 7
GEMS study sites. Cryptosporidium remained a leading cause of MSD in toddlers age 12–23
months, ranking third after rotavirus and Shigella; 5–9% of all MSD cases in 5 of the 7 sites
were attributable to Cryptosporidium [10]. Cryptosporidium-associated MSD negatively
impacted linear growth and significantly increased the risk of death in toddlers [10]. A fol-
low-on study, GEMS-1A, investigated Cryptosporidium in association with less-severe diar-
rhea (LSD) over a 1-year period in 6 of 7 GEMS sites; the LSD cases enrolled in GEMS-1A,
like the MSD cases enrolled in GEMS, were pediatric patients who were brought to health
care facilities.
We extrapolated GEMS site-specific burdens of Cryptosporidium-associated MSD and LSD
in children age<24 months to estimate Cryptosporidium-associated diarrhea burdens for the
entire SSA region (except the Republic of South Africa) and the India/Pakistan/Bangladesh/
Nepal/Afghanistan (I/P/B/N/A) region of South Asia, where ~80% of global young child deaths
due to diarrheal disease occur [17,18].
CryptosporidiumDiarrheal Disease Burden
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Methods
Study design and population
GEMS was a prospective matched case-control study conducted for 36 months at 7 sites where
demographic surveillance systems (DSS) regularly updated censused populations. Sites
included: Basse, The Gambia; Bamako, Mali; Manhiça, Mozambique; Siaya County, Kenya;
Kolkata, India; Mirzapur, Bangladesh; and Bin Qasim Town, Pakistan. The published rationale
[19], working assumptions [20], epidemiological [21], laboratory [22], and statistical methods
[23] of GEMS are summarized below.
The GEMS sampling frame comprised children age<60 months residing within each site’s
DSS area. Children brought to sentinel health centers (SHCs) serving each DSS were assessed
for criteria for MSD (vide infra). Every fortnight, 8–9 cases were targeted for enrollment, per
age stratum (0–11, 12–23 and 24–59 months), per site. Within 14 days of each case enrolled,
we undertook to enroll 1–3 randomly selected age- and sex-matched controls from the same or
nearby communities. MSD was defined as a new acute diarrheal episode (3 loose stools in the
previous 24 hours, occurring after7 diarrhea-free days, and beginning within the previous 7
days), and having some or severe dehydration, initiation of intravenous rehydration based on a
clinician’s judgment, visible blood in stools (dysentery), or hospitalization for diarrhea or dys-
entery. At enrollment, a standardized evaluation, anthropometric measurements, and a stool
sample were obtained from cases and controls. A single follow-up home visit was carried out
~60 (range 49–91) days after enrollment, during which the vital status of cases and controls
was recorded and anthropometric measurements were made.
GEMS-1A was a 1-year extension in which children with MSD and LSD were enrolled at the
SHCs in 6 of 7 GEMS sites, while in Kenya only MSD cases were enrolled. LSD was defined as a
new acute diarrhea case seen at SHCs that did not meet the definition of MSD. Data collection
methods, including the ~60-day follow-up household visit, were otherwise identical to GEMS.
Laboratory procedures
Case and control stool samples were tested for numerous enteropathogens [10,22], including
Cryptosporidium, which was detected using an enzyme immunoassay (EIA) (TechLab, Inc.
Blacksburg, VA). A random subset of stool specimens from 3,809 GEMS MSD case-control
pairs from across all sites was also tested for various enteropathogens using TaqMan Array
Card (TAC)-based real-time polymerase chain reaction (PCR). Briefly, nucleic acid was
extracted from stool specimens using the QIAamp Fast Stool DNAMini kit (Qiagen, Valencia,
CA). The TaqMan Array Card methodology compartmentalizes PCR reactions for 48 targets
per specimen as previously described [24]. For this project we included primers to amplify the
18S rRNA gene of Cryptosporidium species [24] and primers for alleles of the LIB13 locus that
differentiates C. hominis from C. parvum [25]. The LIB13 locus is not known to be present in
other Cryptosporidium species, other than a divergent sequence in C. cuniculus (GU327781).
The assay did not amplify genomic DNA from C.meleagridis isolate TU1867. Specimens with
cycle threshold (CT) values40 were considered positive with the species identification assay.
For specimens that did not yield a LIB13 result, we performed nested amplification of a longer
fragment of the 18S gene rRNA [26], as well as GP60 to try to identify the species [27]. GP60
sequencing was also performed to subtype the available C. parvum and C. hominis specimens.
Estimating the burden attributable to Cryptosporidium
Since Cryptosporidium was incriminated as a cause of MSD and LSD mainly among children
aged<24 months [10], disease burden extrapolations focused on infants 0–11 and toddlers
CryptosporidiumDiarrheal Disease Burden
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12–23 months of age. Details of the analysis are presented in Fig 1. For each site and age group,
pathogen-specific attributable fractions (AFs), weighted according to calendar time and pres-
ence or absence of dysentery and adjusted for the presence of other pathogens, and annual
attributable incidence (AI) rates for MSD during the 3 years of GEMS have been reported [10].
Employing similar methodology [10,23,28], GEMS-1A data were used to estimate Cryptospo-
ridium-attributable incidence of LSD, for site/age groups in which Cryptosporidium was associ-
ated with LSD with P<0.1 after adjustment for other pathogens. Data from GEMS and GEMS-
1A were used to estimate odds ratios (ORs) for Cryptosporidium and MSD by 6-month age
interval for children aged 0–23 months; weighting by time or presence of dysentery should
have little effect on associations with Cryptosporidium, and it was not employed in this
analysis.
Cryptosporidium-specific AFs and AI rates, healthcare utilization rates for MSD and LSD,
along with population estimates for the sites, were used to calculate overall Cryptosporidium-
specific MSD and LSD AI rates separately for the 4 African sites (3 sites for LSD) and 3 Asian
sites. These AI rates were extrapolated to the countries where GEMS sites were located, the 51
countries of the SSA region (excluding Republic of South Africa), and the India/Pakistan/Ban-
gladesh/Nepal/Afghanistan (I/P/B/N/A) region of South Asia. For each country or region, the
Cryptosporidium AI rate was multiplied by the total population (per United Nations estimates)
[29] to generate national and region-wide estimates of annual Cryptosporidium-attributable
MSD and LSD cases. Since GEMS and GEMS-1A were conducted over 5 calendar years, we
used the average UN estimated population size (for each GEMS country and region) of chil-
dren 0–4 years of age during 2005–2010; we divided by 5 to estimate the number of children
aged 0–11 and aged 12–23 months. To estimate 95% confidence intervals (CIs), we took the
2.5th and 97.5th percentiles of the number of Cryptosporidium-attributable diarrhea cases from
100,000 Monte Carlo simulations, assuming normal distributions for relevant parameters, with
standard deviations estimated from Taylor series approximations. The proportions of C. homi-
nis and C. parvum among the subset of cases (by PCR) were multiplied by the total number of
Cryptosporidium-attributable diarrhea cases to estimate the species-specific attributable
burdens.
Two strategies to estimate deaths among Cryptosporidium-associated
diarrhea cases
The number of deaths among children aged<24 months with Cryptosporidium-associated
diarrhea over the ~60-day follow-up period following enrollment provided an extended case
fatality risk (ECFR) [10,21]. However, because GEMS and GEMS-1A were conducted in popu-
lations with high or moderate<5 years mortality, and given numerous risk factors for death
among children with MSD or LSD, some proportion of deaths among Cryptosporidium-associ-
ated diarrhea cases would have occurred unrelated to Cryptosporidium infection. Accordingly,
we utilized two different analytical strategies to estimate more specifically the role of Cryptospo-
ridium in deaths of children with Cryptosporidium-associated diarrheal illness.
Cryptosporidium-attributable deaths among Cryptosporidium-positive
diarrhea cases in the population age <24 months
First, we estimated the Cryptosporidium-attributable ECFR by subtracting the extended fatality
risk (EFR) over the ~60-day observation period in GEMS/GEMS-1A controls from the ECFR
in Cryptosporidium-positive cases. We used deaths in all controls, because the numbers of
deaths among matched controls of Cryptosporidium-positive cases were very small. Multiply-
ing the Cryptosporidium-attributable ECFR by the estimated number of Cryptosporidium-
CryptosporidiumDiarrheal Disease Burden
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004729 May 24, 2016 5 / 20
CryptosporidiumDiarrheal Disease Burden
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004729 May 24, 2016 6 / 20
positive MSD and LSD cases in the region (SSA or I/P/B/N/A) provides a regional estimate of
Cryptosporidium-attributable deaths.
Excess deaths among Cryptosporidium-attributable MSD and LSD
cases
We estimated the excess ECFR in Cryptosporidium-positive MSD and LSD cases relative to the
ECFR in Cryptosporidium-negative cases by subtracting the ECFR in Cryptosporidium-negative
cases from the ECFR in Cryptosporidium-positive cases. This excess risk represents the contri-
bution of Cryptosporidium to death risk beyond both the background risk of death in the gen-
eral pediatric population and that of diarrhea patients. The excess ECFR was then multiplied
by the number of Cryptosporidium-attributable cases in each region, to estimate excess deaths
among Cryptosporidium-attributable cases compared to the expected number of deaths if these
cases had been Cryptosporidium-negative.
Estimates of Cryptosporidium-related deaths for the combined age group 0–23 months were
calculated separately for MSD and LSD for the SSA region, given the much higher ECFR in
children with MSD; deaths were estimated for MSD and LSD combined for the I/P/B/N/A
region. Two-sided 95% CIs for differences in death risks were estimated by the Miettinen and
Nurminen likelihood score method [30]. CIs for numbers of deaths were estimated assuming
normal distributions for numbers of deaths, with variances estimated from Taylor series
approximations.
Statistical significance was defined as a two-sided P-value<0.05. Analyses were performed
using SAS version 9, IBM SPSS version 22, and NCSS 8.
Ethical approval
The study protocol was approved by ethics committees at the University of Maryland, Balti-
more and at each field site [21]. Parents/caregivers of participants provided written informed
consent, and a witnessed consent was obtained for illiterate parents/caretakers.
Results
Patterns of infection and diarrheal illness associated with
Cryptosporidium, by age
Among 15,284 cases (12,110 MSD and 3,174 LSD) and 21,527 matched controls from GEMS-1
and GEMS-1A, Cryptosporidium data were missing for 11 cases (0.07%) and 10 controls
(0.0046%) and these participants were excluded from analyses. Among the total 15,284 MSD
and LSD cases, six (0.039%) had four matched controls rather than a maximum of three; these
six deviations occurred in one African site during GEMS-1. The six extra matched controls
were not censured from the dataset. Overall, Cryptosporidium was detected in stools from 1632
cases (10.7%) and 1184 controls (5.5%) (P<0.001); positivity was significantly higher in MSD
cases than matched controls in the age groups 0–11 and 12–23 months at all sites, and among
the 24–59 month age group in Kenya. Cryptosporidium was also significantly more common in
LSD cases than controls aged 0–11 and 12–23 months in Gambia and India, while in Mali and
Fig 1. Flow chart of steps andmethods used in calculating the burden attributable to Cryptosporidium diarrhea. AF:
attributable fraction, DSS: Demographic Surveillance systems, GEMS: Global Enteric Multicenter Study, HUAS: Health care utilization
and attitudes surveys, region, LSD: less severe diarrhea, MSD: moderate-to-severe diarrhea, OR: odds ratio, SHC: sentinel health
centers * I/P/B/N/A: India, Pakistan, Bangladesh, Nepal and Afghanistan countries of South Asia; SSA: sub-Saharan Africa (excluding
South Africa).
doi:10.1371/journal.pntd.0004729.g001
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Mozambique this was found only in the toddler age group and in Pakistan only in infants and
in children age 24–59 months (Table 1). Adjusted attributable incidence rates of Cryptosporid-
ium LSD by site and age group are shown in Table 2.
When MSD data were examined in narrower age groups, we found significant positive asso-
ciations between Cryptosporidium and MSD at 4 sites (Mali, Mozambique, Kenya, India) in the
first 5 months of life. ORs were higher at age 6–11 months, except in Mali. A significant OR
between Cryptosporidium and MSD was observed in Mali, Mozambique, Kenya and India at
ages 0–17 months. In Gambia and Pakistan, this association was significant from 6–23 months
of age and in Bangladesh only at age 6–11 months. Adjusted AFs increased from age 0–5
months to age 6–11 months and were highest at age 6–11 months, except in Pakistan (Table 3).
Cryptosporidium species
We identified Cryptosporidium species by PCR testing for 18S and Lib13 targets in a random
subset of 3,809 case/control pairs. Samples with unresolved species by Lib13 (which only differ-
entiates C. hominis from C. parvum) had species investigated by 18S and GP60 assays, as
described in the Methods. This revealed 338 EIA+/PCR+ cases and 157 EIA+/PCR+ controls.
Among the 338 samples from Cryptosporidium-positive MSD cases, 333 were suitable for fur-
ther testing, of which 259 (77.8%), 33 (9.9%), 4 (1.2%), and 2 (0.6%), respectively, were positive
for C. hominis, C. parvum, both C. hominis and C. parvum and C.meleagridis; the species of 35
(10.5%) specimens remained undetermined. Corresponding percentages in controls were
68.2%, 8.9%, 0.6%, 0.6%, and 21.0%. The species of one control sample (0.6%) was identified as
C. canis. GP60 subtypes were identified on 71 EIA+/PCR+ specimens including 32 C. hominis,
37 C. parvum, and 2 C.meleagridis. Of 37 C. parvum infections, 34 (91.9%) were anthroponotic
Table 1. Cryptosporidium positivity (by EIA) in cases and controls by age, site, and severity of diarrhea.
Basse, The
Gambia
Bamako, Mali Manhiça,
Mozambique
Siaya County,
Kenya
Kolkata, India Mirzapur,
Bangladesh
Karachi, Pakistan
MSD Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Total number (age
0–11 months)
520 783 961 961 439 883 829 896 878 892 672 1122 788 788
Cryptosporidium (%) 16.0 6.3* 16.6 6.9* 19.8 8.8* 14.4 5.8* 15.3 6.7* 8.2 3.4* 14.1 9.1*
Total number (age
12–23 months)
609 894 911 924 237 517 491 808 752 778 579 967 512 902
Cryptosporidium (%) 12.3 5.0* 9.4 6.9* 16.5 9.9* 11.0 4.8* 14.4 8.2* 6.0 3.3* 10.9 5.7*
Total number (age
24–59 months)
243 503 845 863 137 279 458 744 477 923 463 1111 298 745
Cryptosporidium (%) 3.7 2.2 3.9 3.0 6.6 6.8 4.8 1.7* 9.6 12.0 4.5 5.3 4.7 3.2
LSD Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Total number (age
0–11 months)
220 259 236 236 155 154 NA NA 213 213 183 366 227 228
Cryptosporidium (%) 13.6 5.4* 9.3 6.8 16.1 10.4 7.5 1.9* 4.4 1.9 9.3 3.1*
Total number (age
12–23 months)
202 273 226 227 175 175 NA NA 180 194 148 296 171 309
Cryptosporidium (%) 11.9 4.8* 11.1 5.7* 15.4 6.3* 5.6 1.0* 3.4 2.0 10.5 6.8
Total number (age
24–59 months)
135 250 230 230 101 101 NA NA 181 187 83 248 108 288
Cryptosporidium (%) 7.4 3.6 4.3 2.6 9.9 3.0 3.3 1.6 3.6 2.0 5.6 1.4*
* P < 0.05 for the difference between cases and controls, as obtained in unadjusted conditional logistic regression models.
MSD: moderate-to-severe diarrhea, LSD: less severe diarrhea, EIA: enzyme immune assay, NA: not applicable, the Kenyan site did not enroll LSD cases
in the GEMS-1A component
doi:10.1371/journal.pntd.0004729.t001
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strains: 21 were IIc (19 A5G3 and 2 A4G3); 13 were IIe (1 IIeA6G1, 2 IIeA7G1, 7 IIeA10G1, 2
IIeA11, 1 IIeA15); all three non-anthroponotic strains were IIdA15G1. These derived from
Mali (n = 13), Kenya (n = 9), Mozambique (n = 5), Pakistan (n = 7 including the 3 non-anthro-
ponotic types), Bangladesh (n = 2), and Gambia (n = 1). Samples from Kenya and Mozambique
were mostly IIcA5G3 (12/14). Mali’s strains were diverse; containing 10/11 IIe strains as well
as 3 IIcA5G3. The C. hominis subtypes included Ia (1 A18R2, 1 A19R2, 1 A23R2, 1 A24G1R2,
2 A25R2, 1 A26R2), Ib (3 A9G3, 8 A13G3), Id (1A14), Ie (exclusively 10 A11G3T3), and If (2
A14G1). Both C.meleagridis were subtyped as IIIdA6R1.
Disease burden
The Cryptosporidium-attributable MSD incidence was estimated to be 3.48 (95% CI, 2.27–
4.67) and 3.18 (95% CI, 1.85–4.52) per 100 child-years in the African and Asian sites, respec-
tively, in the 0–11 months age group. The respective incidences for toddlers aged 12–23
months were 1.41 (95% CI, 0.73–2.08) and 1.36 (95% CI, 0.66–2.05) per 100 child-years. Corre-
sponding Cryptosporidium-attributable LSD incidence rates were 2.52 (95% CI, 0.33–5.01) and
Table 2. Adjusted attributable incidence (per 100 child-years) and 95% confidence intervals (CIs) of
Cryptosporidium-attributable LSD, by site and age group*.
Site/ age group (months) Adjusted attributable incidence rate per 100 child-years (95% CI)
Gambia
0–11 4.58 (-0.01–9.53)
12–23 3.49 (-0.01–6.98)
24–59 0.39 (-0.15–0.92)
Mali
0–11 -
12–23 3.92 (-3.10–10.95)
24–59 -
Mozambique
0–11 5.36 (-4.90–15.62)
12–23 5.47 (-1.32–12.26)
24–59 -
India
0–11 4.73 (0.61–8.86)
12–23 3.43 (-0.78–7.64)
24–59 -
Bangladesh
0–11 -
12–23 -
24–59 -
Pakistan
0–11 8.46 (-0.03–16.95)
12–23 10.81 (-1.19–22.81)
24–59 0.93 (-0.24–2.09)
* Weighted adjusted attributable incidence rates were calculated only for site/age groups in which
Cryptosporidium was associated with LSD with P<0.1 in multivariable conditional logistic regression
models that adjusted for the presence of other enteric pathogens.
Note—LSD cases were not enrolled in Kenya during GEMS-1A
doi:10.1371/journal.pntd.0004729.t002
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Table 3. Association betweenCryptosporidium (by EIA) and MSD from age 0–23 months by site during four years of surveillance: matched unad-
justed and adjusted odds ratios (ORs) and adjusted attributable fractions (AF) with 95% confidence intervals (CIs)*.
Site and age
group
(months)
Number
of MSD
cases
Number (%) of
cases positive
for
Cryptosporidium
Number
of
controls
Number (%) of
controls positive
for
Cryptosporidium
Unadjusted
OR (95% CI)
P1 Adjusted OR
(95% CI)
P2 Adjusted
AF (95%
CI)
Gambia
<6 86 7 (8.1) 123 6 (4.9) 1.60 (0.50–
5.18)
0.43 1.99 (0.58–
6.82)
0.28 4.0 (-3.0–
11.1)
6–11 434 76 (17.5) 660 43 (6.5) 4.00 (2.47–
6.47)
<0.0001 4.41 (2.65–
7.35)
<0.0001 13.5 (9.3–
17.8)
12–17 338 45 (13.3) 478 25 (5.2) 2.87 (1.62–
5.08)
0.0003 2.61 (1.38–
4.92)
0.003 8.2 (3.5–
13.0)
18–23 271 30 (11.1) 416 20 (4.8) 2.48 (1.34–
4.61)
0.004 3.23 (1.59–
6.53)
0.001 7.6 (3.1–
12.2)
Mali
<6 230 26 (11.3) 230 4 (1.7) 7.29 (2.34–
22.71)
0.0006 6.59 (2.07–
20.95)
0.001 9.6 (5.1–
14.1)
6–11 731 134 (18.3) 731 62 (8.5) 2.58 (1.83–
3.64)
<0.0001 3.76 (2.48–
5.70) (Giardia
absent)3 1.24
(0.56–2.77)
(Giardia
present)3
<0.0001
0.59
12.3 (8.7–
15.8)
12–17 527 60 (11.4) 533 40 (7.5) 1.70 (1.07–
2.71)
0.025 1.81 (1.10–
2.98)
0.019 5.1 (1.1–
9.1)
18–23 384 26 (6.8) 391 24 (6.1) 1.10 (0.60–
2.01)
0.76 1.06 (0.56–
2.02)
0.85 0.4 (-3.9–
4.7)
Mozambique
<6 153 22 (14.4) 293 26 (8.9) 2.29 (1.18–
4.43)
0.014 2.41 (1.17–
4.98)
0.018 8.4 (2.0–
14.8)
6–11 286 65 (22.7) 589 52 (8.8) 3.67 (2.32–
5.83)
<0.0001 5.71 (3.32–
9.82)
<0.0001 18.7
(13.2–
24.3)
12–17 155 28 (18.1) 330 32 (9.7) 2.45 (1.35–
4.42)
0.003 2.30 (1.19–
4.44)
0.013 10.2 (2.7–
17.8)
18–23 82 11 (13.4) 187 19 (10.2) 1.70 (0.74–
3.91)
0.21 1.80 (0.70–
4.63)
0.22 6.0 (-4.0–
16.0)
Kenya
<6 306 37 (12.1) 329 17 (5.2) 2.44 (1.33–
4.46)
0.004 3.09 (1.55–
6.16)
0.001 8.2 (3.7–
12.7)
6–11 523 82 (15.7) 567 35 (6.2) 2.79 (1.81–
4.31)
<0.0001 3.31 (2.08–
5.27)
<0.0001 10.9 (7.2–
14.7)
12–17 313 38 (12.1) 516 26 (5.0) 3.06 (1.75–
5.37)
<0.0001 3.75 (2.02–
6.95)
<0.0001 8.9 (4.7–
13.1)
18–23 178 16 (9.0) 292 13 (4.5) 2.29 (1.02–
5.17)
0.045 2.43 (1.01–
5.86)
0.048 5.3 (-0.1–
10.7)
India
<6 298 45 (15.1) 301 22 (7.3) 2.35 (1.33–
4.13)
0.003 2.44 (1.34–
4.44)
0.003 8.9 (3.5–
14.3)
6–11 580 89 (15.3) 591 38 (6.4) 2.97 (1.91–
4.63)
<0.0001 3.22 (1.90–
5.47)
<0.0001 10.6 (6.6–
14.6)
12–17 458 65 (14.2) 473 33 (7.0) 2.20 (1.40–
3.47)
0.0007 2.19 (1.23–
3.87)
0.007 7.7 (2.9–
12.5)
18–23 294 43 (14.6) 305 31 (10.2) 1.59 (0.91–
2.77)
0.11 2.09 (0.99–
4.40)
0.054 7.6 (0.9–
14.3)
(Continued)
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4.88 (95% CI, 0.82–8.92) in infants and 4.04 (95% CI, 0.56–7.51) and 4.71 (95% CI, 0.24–9.18)
in toddlers, per 100 child-years.
Applying these incidence rates to the pediatric population age<2 years in the SSA and I/P/
B/N/A regions, respectively, yielded annual estimated CryptosporidiumMSD burdens of ~1.2
million and ~1.5 million cases. The total number of LSD and MSD cases was estimated to be
2.9 million in this age group in SSA and 4.7 million in the populous I/P/B/N/A region
(Table 4). The proportions of cases due to C. hominis and C. parvum in the subset tested for
species were multiplied by the total estimated number of Cryptosporidium-attributable diar-
rhea cases in both regions (~7.6 million), yielding estimates of 5.9 million C. hominis, 0.76 mil-
lion C. parvum and 90,000 thousand co-infected (C. hominis plus C. parvum) cases in children
aged<2 years.
Table 3. (Continued)
Site and age
group
(months)
Number
of MSD
cases
Number (%) of
cases positive
for
Cryptosporidium
Number
of
controls
Number (%) of
controls positive
for
Cryptosporidium
Unadjusted
OR (95% CI)
P1 Adjusted OR
(95% CI)
P2 Adjusted
AF (95%
CI)
Bangladesh
<6 165 7 (4.2) 272 10 (3.7) 1.21 (0.44–
3.33)
0.70 0.92 (0.31–
2.76)
0.88 -0.4 (-4.5–
3.8)
6–11 507 48 (9.5) 850 28 (3.3) 3.06 (1.91–
4.93)
<0.0001 4.39 (2.15–
8.96) (C. jejuni
absent)4 0.79
(0.24–2.59)
(C. jejuni
present)4
<0.00010.70 5.7 (2.3–
9.1)
12–17 341 19 (5.6) 569 18 (3.2) 1.97 (0.99–
3.94)
0.054 2.23 (0.76–
6.54)
0.14 3.1 (-1.1–
7.2)
18–23 238 16 (6.7) 398 14 (3.5) 1.77 (0.84–
3.73)
0.13 0.65 (0.15–
2.78)
0.56 -3.6
(-16.1–
9.0)
Pakistan
<6 315 35 (11.1) 315 27 (8.6) 1.33 (0.78–
2.25)
0.30 1.43 (0.77–
2.65)
0.26 3.3 (-1.8–
8.5)
6–11 473 76 (16.1) 473 45 (9.5) 1.81 (1.22–
2.68)
0.003 2.91 (1.71–
4.93)
(Aeromonas
absent)5 0.64
(0.16–2.60)
(Aeromonas
present)5
<0.0001
0.54
8.5 (3.3–
13.7)
12–17 314 31 (9.9) 550 33 (6.0) 1.81 (1.04–
3.14)
0.036 2.32 (1.24–
4.34)
0.009 5.6 (1.6–
9.6)
18–23 198 25 (12.6) 352 18 (5.1) 2.48 (1.28–
4.79)
0.007 3.09 (1.47–
6.50)
0.003 8.5 (3.3–
13.8)
* Table 3 includes data only from study children with Cryptosporidium results. EIA: enzyme immunoassay
1 These p-values were obtained from unadjusted conditional logistic regression analysis.
2 These p-values were obtained from adjusted conditional logistic regression analysis.
3 There is an interaction (P < 0.1) between Cryptosporidium and Giardia for Mali at age 6–11 months.
4 There is an interaction (P < 0.1) between Cryptosporidium and C. jejuni for Bangladesh at age 6–11 months.
5 There is an interaction (P < 0.1) between Cryptosporidium and Aeromonas for Pakistan at age 6–11 months.
doi:10.1371/journal.pntd.0004729.t003
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Table 4. Estimated number (in thousands) of diarrhea cases attributable to Cryptosporidium by age, country and region§.
Syndrome/age
(months)
Gambia Mali Mozambique Kenya** India Bangladesh Pakistan Sub-
Saharan
Africa†
South
Asia *
MSD
Age 0–11
Number (2.5th-
97.5th percentile)
2.0 (1.4–
2.9)
17.2
(12.0–
25.1)
28.5 (19.9–
41.5)
44.4 (31.1–
64.8)
784.5
(518.0–
1,263.3)
100.9 (66.6–
162.6)
129.6
(85.5–
209.0)
880.5
(616.3–
1,283.3)
1,068.0
(705.5–
1,719.3)
Age 12–23
Number (2.5th-
97.5th percentile)
0.8 (0.5–
1.4)
7.0 (4.1–
11.9)
11.6 (6.8–
19.7)
18.8 (10.6–
30.8)
334.7
(187.0–
576.0)
43.0 (24.0–
74.1)
55.3 (30.8–
95.2)
357.2
(210.2–
610.2)
455.7
(254.6–
784.1)
Age 0–23
Number (2.5th-
97.5th percentile)
2.8 (2.1–
3.8)
24.8
(17.7–
32.7)
41.1 (29.5–
54.0)
64.2 (46.0–
84.3)
1,119.2
(791.7–
1,596.6)
143.9 (101.7–
205.5)
184.8
(130.6–
264.0)
1,237.7
(910.5–
1,671.1)
1,523.8
(1,078.1–
2,172.9)
LSD**
Age 0–11
Number (2.5th-
97.5th percentile)
1.5 (0.2–
4.0)
12.5
(1.4–
34.4)
20.7 (2.3–
57.0)
32.3 (3.6–
88.9)
1,201.7
(314.2–
2,469.2)
154.5 (40.3–
317.4)
198.5
(51.7–
407.6)
639.3 (71.9–
1,761.9)
1,636.1
(427.4–
3,361.4)
Age 12–23
Number (2.5th-
97.5th percentile)
2.3 (-1.5–
9.5)
20.0
(-12.6–
81.8)
33.1 (-20.7–
135.7)
51.6
(-32.4–
211.6)
1,162.1
(219.9–
2,687.4)
149.4 (28.3–
345.6)
191.9
(36.3–
443.8)
1,023.3
(-642.1–
4,192.8)
1,582.1
(299.5–
3,658.1)
Age 0–23
Number (2.5th-
97.5th percentile)
3.8 (-0.7–
12.4)
32.5
(-6.4–
106.6)
53.8 (-10.6–
176.4)
83.9
(-16.6–
275.1)
2,363.8
(1,028.5–
4,301.3)
303.9 (132.2–
553.0)
390.4
(169.7–
710.8)
1,662.6
(-329.0–
5,451.8)
3,218.2
(1,400.5–
5,855.6)
MSD & LSD **
Age 0–11
Number (2.5th-
97.5th percentile)
3.5 (1.8–
6.0)
29.7
(15.8–
52.0)
49.2 (26.3–
86.0)
76.7 (40.9–
134.1)
1,986.3
(1,066.4–
3,334.7)
255.4 (137.1–
428.8)
328.0
(176.0–
551.0)
1,519.8
(811.0–
2,657.7)
2,704.1
(1,451.9–
4,540.0)
Age 12–23
Number (2.5th-
97.5th percentile)
3.1 (-1.0–
10.2)
26.9
(-8.2–
87.5)
44.6 (-13.6–
144.9)
69.7
(-21.3–
226.1)
1,496.8
(545.5–
3,044.6)
192.5 (70.1–
391.4)
247.2
(90.1–
502.9)
1,380.5
(-421.6–
4,479.7)
2,037.8
(742.6–
4,147.8)
Age 0–23
Number (2.5th-
97.5th percentile)
6.6 (1.8–
15.0)
56.6
(15.6–
128.5)
93.8 (25.9–
212.4)
146.4
(40.4–
331.8)
3,483.1
(2,118.7–
5,481.1)
447.8 (271.5–
705.3)
575.2
(348.6–
906.1)
2,900.3
(800.6–
6,575.0)
4,741.9
(2,874.8–
7,462.5)
† Countries and areas included in the extrapolations to sub-Saharan Africa region: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape
Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia,
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Mozambique,
Namibia, Niger, Nigeria, Réunion, Rwanda, Saint Helena, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Swaziland, Togo,
Uganda, United Republic of Tanzania, Zambia, and Zimbabwe [29].
* Extrapolation was made to the most populous countries in South Asia: India, Bangladesh, Pakistan, Afghanistan and Nepal [29].
§ Data presented are estimated absolute numbers of cases attributable to Cryptosporidium, in parentheses are the 2.5th and 97.5th percentiles
(corresponding to 95% conﬁdence intervals), which were estimated by Monte Carlo simulations
** Extrapolation of the combined incidence rate of the 3 African sites of GEMS-1A (Gambia, Mali, Mozambique) was made to the population of Kenya.
doi:10.1371/journal.pntd.0004729.t004
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Cryptosporidium-attributable deaths among Cryptosporidium-positive
diarrhea cases in the population and all diarrhea-attributable deaths
Subtracting the EFR among all controls of MSD cases aged<24 months at African sites (37/
6258, 0.6%) from the ECFR among Cryptosporidium-positive MSD cases (41/643, 6.4%)
(Table 5) yielded a Cryptosporidium-attributable ECFR of 5.8% (95% CI, 4.4%–7.6%). Simi-
larly, subtracting the EFR in controls of LSD cases aged<24 months at African sites (4/1261,
0.3%) from the ECFR among Cryptosporidium-positive LSD cases (1/139, 0.7%) produced an
estimated Cryptosporidium-attributable ECFR of 0.4% (95% CI, -0.4%–3.7%). Multiplying
these Cryptosporidium-attributable ECFRs by the numbers of Cryptosporidium-positive cases
generated estimates of 107,000 Cryptosporidium-attributable MSD deaths (95% CI, 68,200–
151,000) and 16,300 Cryptosporidium-attributable LSD deaths (95% CI, 0–75,200) in the SSA
region. After subtracting the EFR in controls of MSD and LSD cases at Asian sites (6/6758,
0.09%) from the ECFR among Cryptosporidium-positive MSD and LSD cases combined (5/
523, 1.0%) in the Asian sites and multiplying the resultant Cryptosporidium-attributable ECFR
of 0.9% (95% CI, 0.4%–1.9%) by all Cryptosporidium-positive diarrhea cases, we estimate
78,900 (95% CI, 0–159,000) deaths attributable to Cryptosporidium-positive diarrhea in the (I/
P/B/N/A) region. Thus, we estimate a total of ~202,000 Cryptosporidium-attributable diarrhea
deaths in the two regions combined. Using the same methodology, we estimate 455,000 (95%
CI, 280,000–630,000) annual diarrhea-attributable deaths in the SSA region and 254,000 (95%
CI, 13,900–494,000) in the (I/P/B/N/A) region.
Table 5. Extended fatality risk during ~ 60 days following the onset of acute diarrhea among cases and controls aged 0–23months*.
African
sites
Asian sites
Group Total
subjects
No. of deaths during
~60 days of follow-up
Percent
(95% CI)
Total
subjects
No. of deaths during
~60 days of follow-up
Percent (95%
CI)
Total MSD cases 4552 169 3.7% (3.2%-
4.3%)
3828 26 0.7% (0.4%-
1.0%)
Cryptosporidium-positive MSD
cases
643 41 6.4% (4.6%-
8.6%)
451 4 0.9% (0.2%-
2.3%)
Cryptosporidium-negative MSD
cases
3909 128 3.3% (2.7%-
3.9%)
3377 22 0.7% (0.4%-
1.0%)
All controls of MSD cases 6258 37 0.6% (0.4%-
0.8%)
5204 3 0.06%
(0.01%-0.2%)
Controls of Cryptosporidium-
positive MSD cases
928 4 0.4% (0.1%-
1.1%)
573 0 0.0% (0.0%-
0.6%)
Total LSD cases 1139 6 0.5% (0.2%-
1.1%)
1035 5 0.5% (0.2%-
1.1%)
Cryptosporidium-positive LSD
cases
139 1 0.7% (0.1%-
3.9%)
72 1 1.4% (0.3%-
7.5%)
Cryptosporidium-negative LSD
cases
1000 5 0.5% (0.2%-
1.1%)
963 4 0.4% (0.2%-
1.1%)
All controls of LSD cases 1261 4 0.3% (0.1%-
0.8%)
1554 3 0.2% (0.07%-
0.5%)
Controls of Cryptosporidium-
positive LSD cases
156 1 0.6% (0.02%-
3.5%)
102 0 0.0% (0.0%-
3.6%)
* MSD: moderate-to-severe diarrhea (GEMS-1 and GEMS-1A data), LSD: less severe diarrhea (GEMS-1A data). This table includes data only for cases
with Cryptosporidium results and non-missing data on vital status at follow-up, and their matched controls.
doi:10.1371/journal.pntd.0004729.t005
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Excess deaths among Cryptosporidium-attributable MSD and LSD
cases
Subtracting the ECFR of Cryptosporidium-negative MSD cases (3.3%) from the ECFR of Cryp-
tosporidium-positive MSD cases (6.4%) (Table 5) and multiplying the result by the number of
Cryptosporidium-attributable MSD cases in the SSA region indicated that Cryptosporidium was
responsible for an excess ~38,400 (95% CI, 13,400–68,100) MSD deaths among Cryptosporid-
ium-attributable MSD cases. The analogous calculations based on LSD data (Table 5) suggested
that Cryptosporidium led to ~3,600 (95% CI, -31,600–46,000) excess LSD deaths per year. In
Asian sites the estimate of annual excess deaths in children<24 months of age with Cryptospo-
ridium-attributable diarrhea was ~16,900 (95% CI, -20,900–61,100). Thus, between the two
regions we estimate that Cryptosporidium was responsible for ~59,000excess deaths in cases of
Cryptosporidium-attributable diarrhea in children aged<24 months, compared to the expected
deaths in the same number of Cryptosporidium-negative cases.
Discussion
There have been few attempts to estimate the burden of Cryptosporidium diarrheal disease in
large populations. One exception is the Cryptosporidium burden estimate published for India
[31]. Others are the global Cryptosporidium-associated mortality estimates contained within
Global Burden of Disease (GBD) and Child Epidemiology Estimation Group (CHERG) reports
[32–34]. Three obstacles have heretofore impeded attempts to estimate region-wide Cryptospo-
ridium disease burdens, including: 1) marked heterogeneity of clinical and laboratory methods
used in studies of the etiology of pediatric diarrhea; 2) failure to take into account that many
children without diarrhea also excrete Cryptosporidium; 3) a lack of species-specific data from
clinical studies which might guide vaccine development efforts. In this paper, we utilized data-
sets and laboratory tests that allowed these obstacles to be overcome.
GEMS-1, pursued in representative sites in 7 developing countries, documented Cryptospo-
ridium as a leading cause of endemic childhood diarrhea of a severity that brings children to
healthcare facilities, particularly during the first 24 months of life [10]. Importantly, GEMS-1
utilized rigorous standardized clinical, epidemiologic and laboratory methods to collect exten-
sive data over several consecutive years in 7 sites. By including matched control children with-
out diarrhea and adjusting for mixed infections with other enteropathogens, GEMS-1
quantified the specific role of Cryptosporidium in childhood diarrheal disease beyond the back-
ground carriage of Cryptosporidium [10,23]. Finally, our results represent the first systematic,
multisite, geographically-diverse assessment of the species-specific burden of Cryptosporidium-
associated pediatric diarrhea, unequivocally corroborating the dominance of C. hominis [7,35–
38] in infants and toddlers at all sites and revealing that 92% of C. parvum infections were due
to recognized anthroponotic subtypes [39–41].
Despite our cautious extrapolation strategy, we found a substantial disease burden of ~7.6
million diarrhea cases annually attributable to Cryptosporidium, including ~2.9 million in SSA
and ~4.7 million in the I/P/B/N/A region. Our estimated annual number of Cryptosporidium-
attributable diarrhea cases (3.5 million) among Indian children aged<24 months falls within
the lower limit of the burden estimated by Sarkar et al. [31].
GEMS-1 [10] and other studies [8,13,42] have demonstrated a negative impact of Crypto-
sporidium-associated diarrhea on linear growth (stunting), a nutritional insult that increases
the risk for severe or fatal outcomes [43,44]. The Malnutrition and Enteric Infections
(MAL-ED) study prospectively followed birth cohorts in Peru, Brazil, Tanzania, South Africa,
Pakistan, Bangladesh, Nepal and India with twice-weekly household visits through age 24
months [45], thereby detecting mostly mild diarrheal episodes typically not observed in
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healthcare facility-based passive surveillance. Thus, MAL-ED provides data on the etiology of
milder diarrheal illness and revealed Cryptosporidium to be the fifth most important diarrhea-
associated pathogen in the first year of life and seventh most important in the second year of
life [45]. Regional burden estimates that we calculated did not incorporate the burden of milder
clinical forms of Cryptosporidium-associated illness detected by active-surveillance household
visits, as in MAL-ED, and thus probably under-estimates total burden.
The two models of the death burden in children with Cryptosporidium described in this
manuscript demonstrated that among the 4 African sites MSD cases infected with Cryptospo-
ridium at enrollment had a significantly increased ECFR during the subsequent ~60-days [10]
compared to the risk of death in controls and to the risk of death in Cryptosporidium-negative
diarrhea cases. ECFR in children with Cryptosporidium in the African sites was particularly
driven by Mozambique (high HIV prevalence) and rural Gambia (low HIV), suggesting that
factors other than HIV infection, such as malnutrition, play a role in Cryptosporidium-related
deaths in SSA. While overall mortality during the 60-day follow-up was much lower in the
Asian sites [10], nevertheless our estimates indicate a substantial Cryptosporidium-related
death burden because of the enormity of the<2 years population. Our GEMS-based estimates
of deaths under 24 months attributable to Cryptosporidium diarrhea are greater than the esti-
mates reported by GBD (35,200 deaths) [33] and CHERG (12,000) [34] among children age
<5 years. Discrepancies between GBD and CHERG estimates of<5 years diarrheal disease
mortality are recognized [18,46,47]. Our estimates of total diarrhea-attributable deaths
(455,000 and 254,000 in the SSA and I/P/B/N/A regions, respectively) are somewhat larger
than estimates for children<5 years of age for 2011 in a recent review [48]. In large part these
differences are likely because the GEMS estimates are uniquely based on follow-up information
on deaths among laboratory-diagnosed Cryptosporidium-associated diarrhea cases, whereas
CHERG and GBD estimates are based on deaths that occur acutely.
Our observational study design does not permit definitive determination of the direct causa-
tion between Cryptosporidium-positivity and deaths in young children. Nonetheless, the
GEMS-based findings corroborate other results fromWest Africa [9] highlighting Cryptospo-
ridium as a very clear strong signal for children at increased risk for death. From a public health
perspective, this is sufficient to plan interventions aimed at reducing the risk of death in such
high-risk groups.
We observed a general age-specific pattern of Cryptosporidium infection and a strong asso-
ciation with MSD, with documentation of exposure in the first few months of life (in both
cases and controls), a peak adjusted Attributable Fraction at age 6–11 months and a decrease
thereafter (Table 3). We interpret this as reflecting a time-limited (first 5 months of life), pas-
sive protection mediated by maternally-transferred serum IgG as well as secretory IgA antibod-
ies and other protective components of breast milk, despite exposure to the pathogen. Over the
first two years of life, the prevalence of Cryptosporidium positivity in the controls remains
impressively static documenting continuing exposure. However, beginning at ~6 months of
age, clinical episodes of Cryptosporidium-associated diarrheal illness become more common
and continue through age 23 months. By ~24 months of age these clinical and subclinical infec-
tions appear to induce in most toddlers acquired active immunity against further Cryptosporid-
ium clinical illness. Support for this interpretation comes from a cohort study of Bedouin
children in Southern Israel, a population under transition [49]. Serum IgG and IgM antibodies
to a Cryptosporidium oocyst lysate were measured in children ranging from neonates to tod-
dlers age 23 months [49]. High geometric mean titers (GMT) of serum IgG antibodies (of pre-
sumed maternal origin) were recorded at birth. GMT then decreased gradually until age 6
months, after which it increased progressively, as did the incidence of diarrheal illness and
detection of Cryptosporidium in stools [49]. Collectively, these observations can be interpreted
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as indicating that immunity against Cryptosporidium develops following natural exposure to
the pathogen. Measurements of serum anti-gp15 antibody and clinical and sub-clinical infec-
tions were also monitored in a cohort of infants and toddlers in Vellore, India. Children who
lacked anti-gp15 antibodies just before weaning had higher rates of Cryptosporidium infections
(77%) than seropositive children (59%), although with the relatively small numbers in the
cohort the difference did not reach statistical significance (p = 0.076) [50].
Studies of infection-derived immunity in gnotobiotic piglets further support the notion of
acquired immunity to C. hominis, as an initial induced C. hominis gastroenteritis in piglets sig-
nificantly protected them against subsequent re-challenge with C. hominis [51]. Our documen-
tation of the predominance of C. hominis over C. parvum as a pathogen for human infants
implies that vaccine development research should prioritize protection against this species and
against anthroponotic (human host-restricted) subtypes of C. parvum. The lower incidence of
Cryptosporidium disease in infants<6 months old provides a window wherein multiple spaced
doses of a future vaccine administered to infants may elicit protection for the subsequent
increased risk of clinical Cryptosporidium disease encountered from age 6 to 23 months.
Our study has three obvious limitations. While we have extensive data on MSD cases from 7
sites over 4 years, we have only 1-year enrollment of LSD cases from 6 sites. Thus, estimates on
children with LSD are less robust than for MSD. Second, we generated pooled estimates of dis-
ease incidence and mortality for SSA and I/P/B/N/A and assumed each to be representative of
those regions. However, until locally-representative, standardized data become available, our
approach is warranted. That Cryptosporidium appeared important as a pathogen in both urban
and rural, high and low HIV settings, provides evidence that broad extrapolation is justified.
Third, the species of a small fraction of Cryptosporidium-positive specimens remained unre-
solved because, although they were positive by EIA and PCR, we could not amplify the long
fragments of DNA necessary for species-specific sequence determination of samples mostly
with lower parasite load (average 18S PCR Ct 30±4 versus 21±5 for speciated samples, Mann-
Whitney U test P<0.001). That said, non-hominis/non-parvum species appeared to be quite
rare. As for the species, the anthroponotic IIc and IIe were predominant C. parvum subtype
families in this study with a larger portion of IIe than often appreciated [39]. Similar findings
on C. parvum subtypes have been described in India [36]. Of 32 C. hominis infections with
GP60 typing data, the predominant subtype families were Ia, Ib, and Ie. Ia had more diverse
subtypes [40,52], while Ie subtype was exclusively A11G3T3, consistent with previous reports
[36,39]. IbA13G3 infections appear to be common in West Africa. We found these in Mali
(n = 4, 2 in cases) and Gambia (n = 4, all in cases), consistent with the high proportions previ-
ously seen in Ghana [40]. The observation that the C. parvum parasites associated with MSD of
young children in developing countries represent a restricted anthroponotic subset of all C.
parvum is important as it enhances our ability to better understand the epidemiology of crypto-
sporidiosis and helps direct our vaccine development efforts.
Currently, there is little research to develop Cryptosporidium vaccines for humans and only
one licensed drug, nitazoxanide, to ameliorate Cryptosporidium diarrhea in children [53].
However, nitazoxanide is currently not recommended for use in infants<12 months of age,
exhibits little efficacy in HIV-infected hosts and evidence of efficacy from controlled pediatric
trials is limited [53]. The sizable case and death burden of Cryptosporidium in the SSA and I/P/
B/N/A regions where ~80% of global deaths among young children occur calls for govern-
ments, global policymakers, and funding agencies to invest in developing new tools (e.g., vac-
cines) to prevent Cryptosporidium diarrheal illness and improved methods to diagnose and
treat it, while also advocating increased access to improved sanitation and safe water.
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